Dr. Antonio Belenguer Benavides

Datos del profesional

ÁREAS DE ESPECIALIZACIÓN

· Neuroinmunología

· Esclerosis Múltiple

FORMACIÓN

· Licenciado en Medicina por la Universidad de Valencia

· Médico Residente (MIR) Neurología en el Hospital General Universitario de Castellón de la Plana

· Sub-especialización en enfermedades desmielinizantes del Sistema Nervioso Central (University of Medicine and Dentistry of New Jersey, Newark. USA)

· Master en Neuroinmunología (Universidad de Barcelona)

· Master en Esclerosis Múltiple 2021 (European Accreditation Council for Continuing Medical Education)

EXPERIENCIA PROFESIONAL

· Facultativo Especialista en Neurología en el Hospital General Universitari de Castelló desde 2005 hasta la fecha actual.

PUBLICACIONES

1. Alcala C, Quintanilla-Bordas C, Gascon F, Sempere AP, Navarro L, Carcelen-Gadea M, et al. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study. Journal of Neurology. 2022;269(7):3676-81.

2. Landete L, Perez-Miralles F, Garcia S, Belenguer A, Gascon F, Dominguez JA, et al. Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain. Frontiers in Neurology. 2021;12:12.

3. Alcala C, Quintanilla-Bordas C, Gascon-Gimenez F, Sempere AP, Navarro L, Carcelen-Gadea M, et al. Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab. Mult Scler J. 2021;27(2_SUPPL):672-3.

4. Benavides AB, Romero-del-Rincon C, Claramonte-Clausell B. Multiple sclerosis: MRI enhancing lesions related with tropical nights. Mult Scler J. 2019;25:228-.

5. Torre JAG, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, Avila C, Forn C. Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study. Mult Scler J. 2017;23(14):1854-63.

6. Sepulveda-Sanchez JM, Conde-Moreno A, Baron M, Pardo J, Reynes G, Belenguer A. Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study. Oncol Lett. 2017;13(6):4093-100.

7. Sepulveda-Sanchez JM, Conde-Moreno A, Baron M, Pardo J, Reynes G, Belenguer A. Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study (vol 13, pg 4093, 2017). Oncol Lett. 2017;14(4):4410-.

8. Fittipaldi-Marquez MS, Cruz-Gomez AJ, Sanchis-Segura C, Belenguer A, Avila C, Forn C. Exploring Neural Efficiency in Multiple Sclerosis Patients during the Symbol Digit Modalities Test: A Functional Magnetic Resonance Imaging Study. Neurodegener Dis. 2017;17(4-5):199-207.

9. Sanchis-Segura C, Cruz-Gomez AJ, Belenguer A, Marquez MSF, Avila C, Forn C. Increased regional gray matter atrophy and enhanced functional connectivity in male multiple sclerosis patients. Neurosci Lett. 2016;630:154-7.

10. Baltruschat SA, Ventura-Campos N, Cruz-Gomez AJ, Belenguer A, Forn C. Gray matter atrophy is associated with functional connectivity reorganization during the Paced Auditory Serial Addition Test (PASAT) execution in Multiple Sclerosis (MS). Journal of Neuroradiology. 2015;42(3):141-9.

11. Sclarsky DG, Gozalbo AS, Soriano CS, Fabra CV, Clausell BC, Benavides AB. Stroke mimics in stroke code activations: frequency, diagnoses, treatment, and discharge destination. Emergencias. 2014;26(6):437-42.

12. Pardo-Moreno J, Sepulveda J, Conde-Moreno A, Baron M, Reynes G, Belenguer A. A MULTICENTRIC, OBSERVATIONAL, NON INTERVENTIONAL STUDY OF EFFICACY AND SAFETY OF LACOSAMIDE FOR THE TREATMENT OF EPILEPTIC SEIZURES IN PATIENTS WITH BRAIN TUMORS. Neuro-Oncology. 2014;16:1.

13. Cruz-Gomez AJ, Ventura-Campos N, Belenguer A, Avila C, Forn C. The link between resting-state functional connectivity and cognition in MS patients. Mult Scler J. 2014;20(3):338-48.

14. Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barcelo I, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 20082010 in Spain. Neuro-Oncology. 2013;15(6):797-805.

15. Gomez AJC, Campos NV, Belenguer A, Avila C, Forn C. Regional Brain Atrophy and Functional Connectivity Changes Related to Fatigue in Multiple Sclerosis. Plos One. 2013;8(10):8.

16. Forn C, Ripolles P, Cruz-Gomez AJ, Belenguer A, Gonzalez-Torre JA, Avila C. Task-load manipulation in the Symbol Digit Modalities Test: An alternative measure of information processing speed. Brain Cogn. 2013;82(2):152-60.

17. Cruz-Gomez AJ, Campos NV, Belenguer A, Avila C, Forn C. Relationship between cognitive impairment and functional connectivity changes in multiple sclerosis patients during resting state. Mult Scler J. 2012;18:156-7.

18. Simon-Gozalbo A, Peinazo M, Renau J, Arnau J, Soriano C, Belenguer A, et al. Characteristics and Predictors of Stroke Mimics among 333 Code Strokes in Castellon General Hospital (Spain). Neurology. 2011;76(9):A501-A.

19. Gozalbo AS, Beneyto M, Rodriguez-Luna D, Ventura RMV, Benavides AB, Sclarsky DG. Familial multiple cavernomatosis: description of a new mutation. Neurologia. 2011;26(3):184-6.

20. Forn C, Belenguer A, Simon A, Avila C, Gonzalez-Rosas JJ. Variability in Cognitive Presentation of Different Courses of Multiple Sclerosis Revealed by Clusters Analysis. Neurology. 2011;76(9):A83-A.

21. Forn C, Belenguer A, Belloch V, Sanjuan A, Parcet MA, Avila C. Anatomical and functional differences between the Paced Auditory Serial Addition Test and the Symbol Digit Modalities Test. J Clin Exp Neuropsychol. 2011;33(1):42-50.

22. Belenguer A, Forn C, Simon A, Gonzalez-Rosas JJ, Avila C. A Voxel-Based Morphometry Study of Cognitive Impairment in Multiple Sclerosis (MS) Patients. Neurology. 2011;76(9):A484-A5.

23. Pascual AM, Tellez N, Bosca I, Mallada J, Belenguer A, Abellan I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler J. 2009;15(11):1303-10.

24. Merino J, Belenguer A, de las Penyas R, Conde A, Joannes V. NEURONAVIGATION AND BRAIN BIOPSY: SURGICAL TECHNIQUE AND COMPARISON WITH TRADITIONAL STEREOTACTIC METHOD. Neuro-Oncology. 2009;11(6):919-.

25. Forn C, Ventura-Campos N, Belenguer A, Belloch V, Parcet MA, Avila C. A comparison of brain activation patterns during covert and overt paced auditory serial addition test tasks. Hum Brain Mapp. 2008;29(6):644-50.

26. Forn C, Belenguer A, Parcet-Ibars MA, Avila C. Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT). J Clin Exp Neuropsychol. 2008;30(7):789-96.

27. Lincoln JA, Belenguer A, Vidgop E, Cadavid D, Wolansky L, Skurnick JH, et al. Comparison of Betaseron (R) and Copaxone (R) on newly enhancing lesions by monthly 3T MRI with triple dose gadolinium: Secondary outcomes in a 15-month analysis of the BECOME study. Neurology. 2007;68(12):A331-A.

28. Bosca I, Bosca M, Belenguer A, Evole M, Hernandez M, Casanova B, et al. Necrotising cutaneous lesions as a side effect of glatiramer acetate. Journal of Neurology. 2006;253(10):1370-1.

PERTENECE A

· Colegio de Médicos de Castellón de la Plana

· Sociedad Española de Neurología (SEN)

· Sociedad Valenciana de Neurología (SETH)

· Grupo de enfermedades desmielinizantes del SNC de la SEN

· Grupo de Neurooncología de la SEN

· Comité de Neurooncología del Hospital General Univeristari de Castelló

· Comité para el tratamiento de la Esclerosis Múltiple de la Comunidad Valenciana